Clarity Pharmaceuticals

Clarity's copper-67 Supply Agreement with Nusano further bolsters its growing network of US-based suppliers, including NorthStar and Idaho State University Idaho Accelerator Center. Building a reliable, abundant, sustainable and cost-effective supply to allow the swift scale-up of manufacturing when needed is an important step in Clarity's product development strategy as the Company prepares for a registrational Cu-67 SAR-bisPSMA Phase III clinical trial, with outstanding preliminary clinical trial data generated to date and a Fast Track Designation in the US. https://lnkd.in/eZCnw7dQ #radiopharmaceuticals #copper #biotech

The head-to-head Co-PSMA trial of Cu-64 SAR-bisPSMA against standard-of-care PSMA PET agent, Ga-68 PSMA-11, has achieved its primary endpoint with a significantly higher number of prostate cancer lesions detected using Clarity's product in patients with low PSA levels in the biochemical recurrence setting.   Co-PSMA is an investigator-initiated trial led by Prof Louise Emmett at St Vincent’s Hospital Sydney. These results further build on the growing body of evidence of the enhanced diagnostic performance of Cu-64 SAR-bisPSMA compared to SOC PSMA PET agents and support the hypothesis that Cu-64 SAR-bisPSMA can improve early detection of recurrence and staging of prostate cancer in patients with low PSA who are candidates for curative salvage therapy. #prostatecancer #PSMA #radiopharmaceuticals Click here to read more: https://lnkd.in/ggXs8KnP

Data on Clarity’s Cu-64/Cu-67 SAR-bisFAP products, an exciting new generation of radiopharmaceuticals with the potential to target a range of cancer indications with high unmet needs, will be presented at the upcoming World Molecular Imaging Conference (WMIC) 2025 in Anchorage, Alaska by Dr. Michele De Franco.   These products have shown high tumour targeting and retention in FAP-expressing xenograft mice models of cancer, with the dual-targeting Cu-64 SAR-bisFAP showing improved retention compared to the monomer alone, and Cu-67 SAR-bisFAP displaying improved efficacy compared to both Cu-67 SAR-FAP and an industry benchmark, Lu-177 FAP-2286. https://lnkd.in/gKrxSGgB #radiopharmaceuticals #biotech #fap

Clarity confirms that its products and clinical development programs will remain unaffected by the recently announced US-imposed 100% tariff on imports of branded pharmaceutical products that will take effect from October 1.   Clarity’s products, from isotope manufacture to finished product, are made in America for Americans. All of Clarity’s isotope and drug product manufacturers for its US clinical trial sites are located in the US. By building a supply chain that is fully integrated, from high-volume isotope production, to centralised product manufacture, to delivering these ready-to-use diagnostics to imaging sites in every state of the US on time and on demand, Clarity is aiming to build a model that is impervious to current political dynamics. https://lnkd.in/gjRYYwX7 #pharmaceuticals #tariffs #radiopharm  

Clarity is pleased to release its Annual Report for the financial year ended 30 June 2025. Click below to learn more about the significant milestones we achieved during the financial year as we continue to work towards our ultimate goal of improving treatment outcomes for people with cancer. https://lnkd.in/gHXRx24J

Click below to learn more about the exciting milestones Clarity achieved in the last quarter and our plans for future development as we continue to move closer to our ultimate goal of improving treatment outcomes for people with cancer. https://lnkd.in/gFk7VESi #radiopharmaceuticals #biotech

Clarity has successfully completed a $203 million placement with a small group of institutional investors who are close to the Company. With an enviable Balance Sheet, Clarity is well-funded to progress its products towards potential commercialisation.   The placement has received phenomenal support, evidenced by the raising of over $200 million at a 2.2% premium to Clarity’s last closing price and an 18.0% premium to the 15-day VWAP, as well as a substantial premium to the share price observed for almost the entirety of CY2025.   We thank our shareholders for their strong support and look forward to continuing to generate shareholder value growth as we work towards our ultimate goal of improving treatment outcomes for people with cancer. #biotech #radiopharmaceuticals #capitalraise https://lnkd.in/gb47DeBJ

Clarity has successfully completed a $203 million placement with a small group of institutional investors who are close to the Company. With an enviable Balance Sheet, Clarity is well-funded to progress its products towards potential commercialisation.   The placement has received phenomenal support, evidenced by the raising of over $200 million at a 2.2% premium to Clarity’s last closing price and an 18.0% premium to the 15-day VWAP, as well as a substantial premium to the share price observed for almost the entirety of CY2025.   We thank our shareholders for their strong support and look forward to continuing to generate shareholder value growth as we work towards our ultimate goal of improving treatment outcomes for people with cancer. #biotech #radiopharmaceuticals #capitalraise https://lnkd.in/gb47DeBJ

The investigator-initiated Co-PSMA trial has successfully completed study enrolment with all 50 participants imaged. The study is led by Prof Louise Emmett at St Vincent's Hospital Sydney and is evaluating the performance of Clarity’s diagnostic product, Cu-64 SAR-bisPSMA, in comparison to standard-of-care Ga-68 PSMA-11 for the detection of prostate cancer recurrence.   If the results of this trial support previous findings and confirm that Cu-64 SAR-bisPSMA can detect more lesions than Ga-68 PSMA-11, this could change the treatment landscape for prostate cancer, allowing for earlier visualisation of lesions which is crucial for physicians to determine the optimal course of treatment before the cancer spreads, leading to improved outcomes, including the potential for cure. https://lnkd.in/gckCXCP7 #radiopharm #diagnostics #prostatecancer

Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for Cu-64 SAR-bisPSMA. SpectronRx’s facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and Cu-64 SAR-bisPSMA under one roof and enables distribution to all 50 states. With the ability to produce up to 400,000 patient-ready doses annually at the facility and an option to expand into similar additional sites across the US, Clarity is now well-positioned to fulfil the growing needs of clinicians and patients across the country on all levels: nationally, regionally and locally. This Agreement, combined with other supply and manufacturing agreements for isotope and finished product we have secured to date, ensures that Clarity is ready to roll out large-scale manufacturing and distribution of Cu-64 SAR-bisPSMA on day one of commercialisation. Click here to read more: https://lnkd.in/gc7WqW8K #radiopharmaceuticals #PSMA #biotech